Market context and investor reaction
Since an algorithmic stock selection added AbbVie on August 1, the shares have climbed 16.8%, including a 6.0% rise over the most recent month while the broader market moved lower. That performance underscores a shift in investor allocations within pharmaceuticals toward companies demonstrating commercial durability amid patent expirations.
Quarterly results that tell a different story
AbbVie's third-quarter operating disclosure revealed adjusted earnings per share of $3.82, above consensus expectations of $3.74, and total revenue of $17.4 billion. The company reported operational sales growth of 10.5%. At the same time, global sales of Humira continued to decline, falling 30.6% to $683 million for the quarter. Despite that decline, management raised its full-year guidance, now targeting adjusted EPS between $13.95 and $13.99 and revenue of roughly $67.8 billion.
Where growth is coming from
The bulk of AbbVie's recent commercial momentum has come from its next-generation immunology medicines. Skyrizi posted year-over-year revenue growth of 22.9% in the quarter to nearly $5.8 billion, while Rinvoq grew 24.3% to $2.7 billion. Management has set full-year sales guidance for Skyrizi and Rinvoq at $21.8 billion and $10.3 billion, respectively. Company commentary highlights that Skyrizi is capturing about half of new patient treatment starts across psoriasis and inflammatory bowel disease, a penetration rate the company views as supportive of a sustained commercial advantage.
Beyond immunology, AbbVie identified neuroscience as a solid secondary growth engine. Neuroscience revenues expanded 19.5% year-over-year to nearly $3.4 billion in the quarter, driven by broader adoption of products including Vraylar and Botox Therapeutic. Management raised its full-year neuroscience revenue outlook to $13 billion, and reported that nine commercial therapies across the portfolio delivered double-digit sales increases during the quarter.
Cash flow and shareholder returns
Operational performance has translated into meaningful cash generation. AbbVie recorded approximately $14 billion of operating cash flow in the first nine months of 2026. That cash has been used to fund strategic, bolt-on deals such as Apogee Therapeutics and to support shareholder returns. The company increased its quarterly dividend by 5.2% to $1.82. Counting legacy years within Abbott Laboratories, AbbVie has extended its annual dividend increase streak to 52 consecutive years, and the payout yields about 2.5% at current levels.
Valuation and analyst expectations
Market multiples reflect a transition in expectations. Trailing earnings multiples appear elevated at 49.5 times, while the stock trades at roughly 21.0 times forward earnings estimates and shows a PEG ratio of 0.15. Consensus projections compiled by the same analyst model used in the stock-selection system anticipate earnings per share rising from $14.04 this year to $16.25 in 2027. The median analyst price target sits at $306.42, compared with recent trading near $291.31.
Concentration risk and patent timeline
Product concentration remains the central long-term risk. Skyrizi and Rinvoq together represented nearly 49% of net revenue in the third quarter. Skyrizi's initial U.S. patent protections begin to expire in 2033, a date investors and analysts are monitoring while reviewing immunology adoption trends, neuroscience revenue durability and dividend coverage metrics in detailed research reports.
Strategy positioning and sector implications
The case of AbbVie illustrates how aggressive commercial execution can blunt the financial impact of a major patent expiration. By replacing a substantial portion of Humira's revenue with high-margin immunology and neuroscience sales sooner than many anticipated, the company has maintained free cash flow and a path for dividend growth without materially increasing balance-sheet risk.
Model-driven stock selection tools have kept AbbVie in strategies aimed at outperforming the S&P 500 and at identifying resilient healthcare operators. Within an active healthcare portfolio for November, AbbVie is grouped alongside firms focused on commercial HIV and oncology therapeutics, operators executing specialty healthcare turnarounds, and firms supplying precision laboratory instruments. The strategy allocates across commercial therapeutics, medical technology and clinical diagnostics.
For investors interested in the model-generated ideas, full access to the collection of algorithmic strategies is available for a stated monthly fee of $9.
Summary of key metrics
- Third-quarter adjusted EPS: $3.82 versus $3.74 consensus
- Total revenue: $17.4 billion; operational sales growth: 10.5%
- Humira sales: $683 million, down 30.6%
- Skyrizi revenue: nearly $5.8 billion, up 22.9%
- Rinvoq revenue: $2.7 billion, up 24.3%
- Guidance: full-year adjusted EPS $13.95 to $13.99; revenue ~ $67.8 billion
- Operating cash flow (first nine months of 2026): approx. $14 billion
- Dividend: $1.82 per quarter after a 5.2% increase; 52-year consecutive increase streak (including legacy Abbott years); yield ~2.5%
- Valuation: trailing earnings multiple 49.5x; forward multiple ~21.0x; PEG 0.15
- Consensus EPS: $14.04 (this year) to $16.25 (2027); median price target $306.42; recent trading near $291.31